Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 6Recruiting 3Active not recruiting 3Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 26Pancreatic Neoplasms 12Stomach Neoplasms 11Colonic Neoplasms 9Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 7Adenocarcinoma Of Esophagus 7Burkitt Lymphoma 6Neoplasms 5Cholangiocarcinoma 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Lung Neoplasms 2Leukemia, Biphenotypic, Acute 2Leukemia 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Urachal cancer 1Unresectable Colorectal Cancer 1

Interventions

Paclitaxel 8Radiotherapy 7Cisplatin 6pembrolizumab 4Fluorouracil 4Surgical Procedures, Operative 3Radiation 3Oxaliplatin 3Levoleucovorin 3Leucovorin 3Esophagectomy 3Drug Therapy 3Carboplatin 3tislelizumab 2lenvatinib 2durvalumab 2Taxes 2TP protocol 2Radiotherapy, Intensity-Modulated 2Nivolumab 2Neoadjuvant Therapy 2Irinotecan 2Capecitabine 2trifluridine tipiracil drug combination 1palbociclib 1osimertinib 1obinutuzumab 1nedaplatin 1naptumomab estafenatox 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Squamous Cell Carcinoma × Leucovorin × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04949256 2025-12-15

MK-7902-014

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
864 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡